uracil and piperidines
uracil has been researched along with piperidines in 285 studies
Research
Studies (285)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (1.05) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (7.72) | 29.6817 |
| 2010's | 225 (78.95) | 24.3611 |
| 2020's | 35 (12.28) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Iakovlev, NN | 1 |
| Chimitova, TA; Grachev, MA; Knorre, DG | 1 |
| BUTTINI, A; GALIMBERTI, P; GEROSA, V; KRAMER, M; MELANDRI, M | 1 |
| Chmielowiec, U; Leś, A; Szelejewski, W | 1 |
| Arias, F; Currie, CA; Halsall, HB; Heineman, WR; Limbach, PA; Seliskar, CJ; Wehmeyer, KR | 1 |
| Asakawa, T; Feng, J; Gwaltney, SL; Kaldor, SW; Kassel, DB; Navre, M; Shi, L; Skene, RJ; Stafford, JA; Takeuchi, K; Wallace, MB; Webb, DR; Xu, R; Zhang, Z | 1 |
| Baldwin, AS; Oettinger, M; Struhl, K | 1 |
| Deacon, CF | 1 |
| Christopher, R; Covington, P; Davenport, M; Fleck, P; Karim, A; Mekki, QA; Wann, ER | 2 |
| Asakawa, T; Kataoka, O; Moritoh, Y; Odaka, H; Takeuchi, K | 3 |
| Asakawa, T; Christopher, RJ; Kassel, DB; Lee, B; Shi, L; Takeuchi, K | 1 |
| DeFronzo, RA; Fleck, PR; Mekki, Q; Wilson, CA | 1 |
| Gwaltney, SL | 1 |
| Fleck, PR; Kipnes, MS; Mekki, Q; Pratley, RE; Wilson, C | 1 |
| Ellis, GC; Fleck, PR; Mekki, Q; Nauck, MA; Wilson, CA | 1 |
| Pratley, RE | 1 |
| Argyrakopoulou, G; Doupis, J | 1 |
| Asakawa, T; Kataoka, O; Moritoh, Y; Odaka, H; Suzuki, N; Takeuchi, K | 1 |
| Fleck, P; Karim, A; Laurent, A; Mekki, Q; Munsaka, M; Wann, E | 1 |
| Fleck, PR; Mekki, Q; Pratley, RE; Reusch, JE; Wilson, CA | 1 |
| Fleck, PR; Gross, JL; Mekki, Q; Rendell, MS; Rosenstock, J; Wilson, CA | 1 |
| Fleck, PR; McCall, T; Mekki, Q; Pratley, RE; Wilson, CA | 1 |
| Christopher, R; Covington, P; Davenport, M; Fleck, P; Karim, A; Li, X; Mekki, Q; Wann, E | 1 |
| Hazama, M; Moritoh, Y; Takeuchi, K | 1 |
| Cefalu, WT | 1 |
| Kuritzky, L | 1 |
| Scheen, AJ | 4 |
| Gerich, J | 1 |
| Fleck, PR; Inzucchi, SE; Mekki, Q; Rosenstock, J; Seufert, J; Wilson, CA | 1 |
| Huang, Y; Li, Y; Lopes-Virella, MF; Schuyler, CA; Ta, NN | 2 |
| Cersosimo, E; DeFronzo, RA; Triplitt, C | 1 |
| Deshpande, SS; Ghatak, SB; Panchal, SJ; Patel, DS; Shanker, N; Srivstava, A | 1 |
| Scott, LJ | 1 |
| Chen, F; Chen, L; Dai, R; Deng, J; Hu, W; Lan, X; Li, C; Lin, Z; Peng, L; Xu, H; Yang, L; Zhang, G; Zhang, X; Zhou, Y | 1 |
| Kaneto, H; Kato, K; Kawashima, S; Matsuhisa, M; Matsuoka, TA; Shimomura, I; Tochino, Y; Yamamoto, K; Yamamoto, T | 1 |
| Huang, Y; Wang, J; Wang, Z; Zhang, X | 1 |
| Fujita, T; Hiroi, S; Takeuchi, K | 1 |
| Boudes, P; Viereck, C | 1 |
| White, JR | 1 |
| Bourdel-Marchasson, I; Dejager, S; Schweizer, A | 1 |
| Gallwitz, B | 1 |
| Kaku, K; Tanabe, A | 1 |
| Ueki, K | 1 |
| Hirayama, M; Hiroi, S; Itayasu, T; Kaku, K; Seino, Y | 1 |
| Bosi, E; Ellis, GC; Fleck, PR; Wilson, CA | 1 |
| Fujita, T; Hirayama, M; Hiroi, S; Kaku, K; Seino, Y | 2 |
| Coppey, LJ; Dake, B; Davidson, EP; Yorek, MA | 1 |
| Bakris, GL; Bergenstal, RM; Cannon, CP; Cushman, WC; Fleck, P; Heller, S; Mehta, C; Nissen, SE; Perez, A; White, WB; Wilson, C; Zannad, F | 1 |
| Deiuliis, JA; Durairaj, R; Kampfrath, T; Lu, B; Maiseyeu, A; Mihai, G; Moffatt-Bruce, S; Pineda, C; Rajagopalan, S; Shah, Z; Sun, Q; Xu, X; Ying, Z; Zhong, J | 1 |
| Alter, M; Chaykovska, L; Fuchs, H; Heiden, S; Hocher, B; Klein, T; Rahnenführer, J; Runge, F; von Websky, K | 1 |
| MacMillan, DW; Nagib, DA | 1 |
| Barbee, T; Correa, I; Fredrickson, J; Gibbs, JP; Gibbs, MA; Lin, SL; Smith, B | 1 |
| Cederholm, J; Diamant, M; Eeg-Olofsson, K; Eliasson, B; Fleck, P; Möller-Goede, D; Smith, U; Taskinen, MR; Wilson, C | 1 |
| Kutoh, E; Ukai, Y | 1 |
| Andukuri, R; Drincic, A; Rendell, M | 1 |
| Burant, CF; DeFronzo, RA; Fleck, P; Mekki, Q; Pratley, RE; Wilson, C | 1 |
| Edwards, KL; Irons, BK; Stapleton, MR; Weis, JM | 1 |
| Agrawal, R; Bahare, RS; Dikshit, SN; Ganguly, S; Jain, P | 1 |
| Hirayama, M; Hiroi, S; Kaku, K; Miyata, Y; Seino, Y | 1 |
| Ishikawa, M; Yamada, Y | 1 |
| Drucker, DJ; Gerasimova, M; Masuda, T; Murray, F; Rieg, T; Rose, M; Tang, T; Vallon, V | 1 |
| Hamaguchi, T; Ikawa, T; Katsuno, T; Kusunoki, Y; Matsuo, T; Miuchi, M; Miyagawa, J; Miyakoshi, K; Murai, K; Myojin, M; Namba, M; Ochi, F; Tokuda, M | 1 |
| Abe, M; Fujii, Y; Higuchi, T; Ito, M; Maruyama, N; Matsumoto, S; Mizuno, M; Okada, K; Soma, M; Suzuki, H | 1 |
| Ito, H; Kohno, K; Kusano, K; Miyoshi, T; Morita, H; Nakamura, K; Noda, Y; Oe, H; Ohno, Y; Toh, N | 1 |
| Itoh, H; Saisho, Y | 1 |
| Bakris, GL; Flynn, C | 1 |
| Fleck, P; Hisada, M; Menon, V; Munsaka, M; Pratley, R; White, WB; Wilson, C | 1 |
| Akahoshi, F; Ishii, S; Kadowaki, T; Kishida, H; Miyaguchi, I; Nabeno, M; Tanaka, Y | 1 |
| Ayaori, M; Iizuka, M; Ikewaki, K; Iwakami, N; Komatsu, T; Murakami, T; Nakaya, K; Ogura, M; Sasaki, M; Sato, H; Takase, B; Takiguchi, S; Uto-Kondo, H; Yakushiji, E; Yogo, M | 1 |
| Fleck, P; Rosenstock, J; Wilson, C | 1 |
| Bond, T | 1 |
| Akema, N; Aoki, K; Enomoto, H; Hasegawa, M; Ito, Y; Kamiko, K; Kawasaki, S; Masuda, K; Nagakura, M; Nakajima, S; Shimotomai, H; Shinoda, K; Takihata, M; Terauchi, Y; Toumura, S; Tsunoda, S | 1 |
| Iihara, K; Kataoka, H; Nakajo, Y; Yanamoto, H; Yang, D | 1 |
| Charbonnel, B; Dejager, S; Schweizer, A | 1 |
| Gelbrich, T; Griesser, UJ; Kahlenberg, V | 1 |
| Bell, GI; Chong, AS; Grossman, EJ; Misawa, R; Park, SY; Tao, J; Wang, XJ; Witkowski, P; Yin, H; Zhong, R | 1 |
| Fujita, K; Goto, Y; Gotoh, H; Inagaki, M; Inoue, M; Nakamura, Y; Oguchi, K; Shimizu, T | 1 |
| Bao, W; Hasegawa, T; Hirata, K; Morimoto, K; Okada, K; Okita, Y; Sasaki, N; Yamashita, T | 1 |
| Eto, T; Hayakawa, M; Hirayama, N; Kario, K; Kitamura, K; Koga, M; Kuroki, K; Matsuo, T; Mishima, O; Nagata, N; Nishino, Y; Sagara, S; Sakata, K; Takeuchi, M; Tamaki, N; Watanabe, R; Yamagishi, S; Yano, Y; Yokota, N | 1 |
| Gosho, M; Jinnouchi, H; Kaneto, H; Katakami, N; Kosugi, K; Kuribayashi, N; Mita, T; Onuma, T; Osonoi, T; Shimomura, I; Shiraiwa, T; Umayahara, Y; Watada, H; Yamamoto, T; Yokoyama, H; Yoshii, H | 2 |
| Blumenthal, E; Bray, E; Krishnan, V; Lai-Hsu, C; Lee, JK; Luo, X; Lyapichev, K; Park, KK; Ramos, J; Soderblom, C; Tsoulfas, P | 1 |
| Bakris, GL; Bergenstal, RM; Cannon, CP; Cushman, WC; Fleck, PR; Heller, SR; Kupfer, S; Mehta, CR; Nissen, SE; Perez, AT; White, WB; Wilson, C; Zannad, F | 1 |
| Hu, W; Lu, X; Tu, Z; Wang, S; Xie, H; Xu, H; Yang, L; Zeng, L; Zeng, S; Zhang, G; Zhang, X; Zhao, X | 1 |
| Cohen, D | 1 |
| Lim, GB | 1 |
| Greenhill, C | 1 |
| Capuano, A; Esposito, K; Giugliano, D; Maiorino, MI; Rossi, F; Sportiello, L | 1 |
| Doi, K; Hamasaki, Y; Katagiri, D; Nangaku, M; Negishi, K; Noiri, E; Okamoto, K | 1 |
| Mitka, M | 1 |
| Fujita, H; Hayashi, H; Kikuchi, N; Komatsu, K; Komatsu, T; Murayama, H; Narita, T; Ohshiro, H; Sato, S; Taniai, H; Yamada, Y | 1 |
| Cabrera, A; Charron, D; Jarvis, CI | 1 |
| Czogalla, J; Eguchi, A; Feldstein, AE; Fu, Y; Gerasimova, M; Kuczkowski, A; Masuda, T; Rose, MA; Scadeng, M; Vallon, V | 1 |
| Erowele, G; Ndefo, UA; Okoli, O | 1 |
| Goto, C; Mizui, T; Ohta, H; Tachi, T; Teramachi, H; Toyoshima, M; Tsuchiya, T | 1 |
| Fleck, P; Pratley, RE; Wilson, C | 1 |
| Diamant, M; Eliasson, B; Fleck, P; Mari, A; Möller-Goede, DL; Smith, U; Taskinen, MR; Tura, A; van Genugten, RE; Van Raalte, DH; Wilson, C | 1 |
| Hussar, DA | 1 |
| Bu, RF; Gu, W; Han, P; Ji, QH; Jiang, ZS; Lei, MX; Li, CJ; Li, L; Li, WH; Li, XF; Li, XJ; Li, ZF; Liu, JD; Liu, XM; Liu, Y; Liu, ZM; Lu, JM; Lü, XF; Pan, CY; Peng, YD; Qu, S; Shi, BY; Song, QH; Xu, XJ; Xue, YM; Yan, L; Yang, JK; Zeng, JE; Zheng, BZ | 1 |
| Standl, E | 1 |
| White, WB; Zannad, F | 1 |
| Mugishima, K; Murasawa, T; Ohno, D; Otsuka, T; Otsuka, Y; Sakai, Y; Sumi, Y; Suzuki, A; Tsuruoka, S | 1 |
| Cole, SW; Marino, AB | 1 |
| Tibaldi, JM | 1 |
| Fujii, M; Fujimaru, R; Hashimoto, Y; Hatake, K; Hosokawa, Y; Kawakita, R; Nakajima, H; Tamagawa, N; Yorifuji, T | 1 |
| Kaneto, H; Katakami, N; Matsuoka, TA; Shimomura, I; Shiraiwa, T; Takahara, M | 1 |
| Béni, S; Fejős, I; Hu, W; Sohajda, T; Szente, L; Urbancsok, Z; Zhou, W | 1 |
| OuYang, P; Sun, L; Wei, P; Zhou, W; Zhou, Y; Zou, Q | 1 |
| Mullard, A | 1 |
| Bettaieb, A; Cummings, BP; Graham, JL; Haj, FG; Havel, PJ; Stanhope, K | 1 |
| Seino, Y; Yabe, D | 2 |
| Dimmitt, SB; Doggrell, SA | 1 |
| Davis, TM | 2 |
| Fujigaki, Y; Fujikura, T; Isobe, S; Iwakura, T; Kato, A; Naito, Y; Ohashi, N; Ono, M; Sakao, Y; Tsuji, N; Tsuji, T; Yasuda, H | 1 |
| Athyros, VG; Elisaf, MS; Filippatos, TD | 1 |
| Ding, YY; Hu, WH; Song, HR; Wang, SC; Xie, H; Zeng, LL; Zeng, SG | 1 |
| Gallwitz, B; Nitschmann, S | 1 |
| Hernandez, GT; Mukherjee, D; Nwosu, AC; Said, S | 1 |
| Kong, L; Lai, ZW; Li, C; Liu, J; Sun, H; Wen, X | 1 |
| Vigili de Kreutzenberg, S; Violini, R | 1 |
| Camisasca, R; Del Prato, S; Fleck, P; Wilson, C | 1 |
| Aoki, H; Hamasaki, T; Hara, K; Hori, K; Inukai, T; Naruse, R; Sakurai, S; Shuutou, H; Suetsugu, M; Suzuki, T; Takebayashi, K; Terasawa, T; Tsuchiya, T | 1 |
| Kaku, K; Kanoo, T; Katou, M; Mori, M; Seino, Y | 1 |
| Hirate, M; Kaneoka, N; Kutoh, E | 1 |
| Inagaki, N; Kadowaki, T; Nakamura, J; Nishimura, R; Shimomura, I; Tanizawa, Y; Ueki, K; Watada, H; Yamada, Y; Yamazaki, T | 1 |
| Clifton, P | 1 |
| Inagaki, N; Kaku, K; Kuroda, S; Maezawa, H; Onouchi, H | 1 |
| Higashijima, Y; Nangaku, M; Tanaka, S; Tanaka, T; Yamaguchi, J | 1 |
| Liu, J; Wang, H; Zhao, H | 1 |
| Bouchard, R; Pugazhenthi, S; Qin, L | 1 |
| Asakura, M; Asano, Y; Asanuma, H; Ihara, M; Kato, H; Kitakaze, M; Minamino, T; Mochizuki, N; Mori, H; Shinozaki, Y; Sugimachi, M; Yamazaki, S | 1 |
| Hirai, M; Inden, Y; Murohara, T; Shimano, M; Takefuji, M; Tsuji, Y; Yamamoto, T; Yanagisawa, S; Yoshida, N | 1 |
| Schnell, O; Standl, E | 1 |
| Bakris, GL; Cannon, CP; Cushman, WC; Fleck, PR; Kupfer, S; Lam, H; Mehta, CR; Menon, V; Perez, AT; White, WB; Wilson, C; Zannad, F | 1 |
| Dicembrini, I; Mannucci, E | 1 |
| Akita, K; Daida, H; Isoda, K; Shimada, K | 1 |
| Cai, Y; Lydic, TA; Olson, LK; Reid, GE; Turkette, T | 1 |
| Nagai, Y | 1 |
| Burciu, C; Koska, J; Reaven, P; Sands, M | 1 |
| Keating, GM | 1 |
| Saisho, Y | 1 |
| Hamamoto, S; Hashiramoto, M; Hirukawa, H; Kaku, K; Kaneto, H; Kimura, T; Kohara, K; Obata, A; Okauchi, S; Shimoda, M; Tawaramoto, K | 1 |
| Kusunoki, M; Miyata, T; Nakamura, T; Natsume, Y; Oshida, Y; Sato, D; Tsutsui, H; Tsutsumi, K | 1 |
| Hirate, M; Kutoh, E; Wada, A | 1 |
| Chen, XW; Duan, W; He, ZX; Yang, T; Yang, YX; Zhang, X; Zhou, SF; Zhou, ZW | 1 |
| Kaji, T; Nonogaki, K | 2 |
| Igeta, M; Kaku, K; Katou, M; Ohira, T; Sano, H | 1 |
| Hirshberg, B; Katz, A | 1 |
| Hayakawa, M; Kobori, H; Mizushige, T; Nishijima, Y; Nishiyama, A; Sakata, K; Yano, Y | 1 |
| Davis, C; Riche, DM | 1 |
| Derosa, G; Maffioli, P | 2 |
| Hülsmann, M; Neuhold, S; Pacher, R | 1 |
| Kupfer, S; White, WB; Zannad, F | 1 |
| Bhamidipati, RK; Gilibili, RR; Mullangi, R; Srinivas, NR | 1 |
| Kaku, K | 1 |
| Czerniak, R; Naik, H; Vakilynejad, M | 1 |
| Špinar, J; Špinarová, L; Vítovec, J | 1 |
| Aoyama, M; Bando, YK; Kawase, H; Monji, A; Murohara, T | 1 |
| Bu, R; Gu, W; Han, P; Ji, Q; Jiang, Z; Lei, M; Li, C; Li, L; Li, W; Li, X; Li, Z; Liu, J; Liu, X; Liu, Y; Liu, Z; Lu, J; Lyu, X; Pan, C; Peng, Y; Qu, S; Shi, B; Song, Q; Xu, X; Xue, Y; Yan, L; Yang, J; Zeng, J; Zheng, B | 1 |
| Baker, WL; White, WB | 1 |
| Duh, D; Van Genechten, D | 1 |
| Chaudhari, P; Del Prato, S; Fleck, P; Wilson, C | 1 |
| Aronson, JK; Langford, O; Stevens, RJ; van Valkenhoef, G | 1 |
| Chong, T; Pugazhenthi, S; Qin, L; Rodriguez, R | 1 |
| Bonora, E; Cigolini, M | 1 |
| Hirate, M; Kutoh, E; Murayama, T; Wada, A | 1 |
| Jermendy, G | 1 |
| Hu, P; Jiang, J; Liu, D; Liu, Y; Ma, X; Shi, C; Wu, F; Zhou, H | 1 |
| Chan, J; Han, P; Hsieh, AT; Ji, Q; Li, C; Li, W; Lu, J; Pan, C; Yang, J; Zeng, J | 1 |
| Bakris, GL; Cannon, CP; Cushman, WC; Kupfer, S; Liu, Y; Mehta, CR; Menon, V; Shimada, YJ; White, WB; Wilson, C; Zannad, F | 1 |
| Fukui, K; Hibi, K; Kishi, S; Michishita, I; Nozue, T; Sozu, T; Takamura, T | 1 |
| Hang, T; Li, Z; Lu, Y; Song, M; Yang, D | 1 |
| Bakris, GL; Bergenstal, RM; Cannon, CP; Cushman, WC; Fleck, PR; Heller, SR; Kupfer, S; Lei, L; Mehta, CR; Nissen, SE; White, WB; Wilson, CA; Zannad, F | 1 |
| Grimshaw, CE; Jennings, A; Kamran, R; Kinugawa, Y; Kosaka, T; Koumura, E; Nishigaki, N; Sano, H; Shi, L; Takeuchi, K; Tani, A; Ueno, H | 1 |
| Cahn, A; Raz, I; Schernthaner, G | 1 |
| Bakris, GL; Bergenstal, RM; Cannon, CP; Cushman, WC; Heller, SK; Kupfer, S; Mehta, CR; Nissen, SE; White, WB; Wilson, CA; Zannad, F | 1 |
| Bingham-Gardiner, P; Bolodeoku, J; Hassan, SW; Lee, S; Scowcroft, A; Spencer, W; Tebboth, A | 1 |
| Cheng, XW; Hao, CN; Hayashi, M; Kikuchi, R; Matsushita, T; Murohara, T; Nakamura, S; Nakayama, T; Takeshita, K; Uchida, Y; Wu, H; Yamamoto, K; Yisireyili, M | 1 |
| Dong, QY; Kuang, JS; Li, LB; Liu, XG; Tai, H; Wang, MY; Zhao, YP | 1 |
| Fukui, K; Gyotoku, D; Iguchi, K; Iinuma, N; Iwasawa, T; Kato, S; Kimura, K; Kirigaya, H; Kusakawa, Y; Nakachi, T | 1 |
| Bodiwala, KB; Marolia, B; Prajapati, P; Shah, S; Thakor, J | 1 |
| Raz, I; Tkáč, I | 1 |
| Hernández, C; Simó, R | 1 |
| Arulmozhiraja, S; Ishitsubo, E; Matsuo, N; Okazaki, S; Shimano, H; Tokiwa, H | 1 |
| Arao, T; Hajime, M; Kuno, F; Kurozumi, A; Mine, S; Miyazaki, M; Mori, H; Narisawa, M; Okada, Y; Sonoda, S; Sugai, K; Tanaka, K; Tanaka, Y; Torimoto, K | 1 |
| Mannucci, E; Monami, M | 1 |
| Kaku, K; Katou, M; Kinugawa, Y; Nishiyama, Y; Sumino, S | 1 |
| Kimura, K; Takayanagi, R; Uchida, T; Yamada, Y | 2 |
| Dudkowski, C; Liu, J; Schmidt, E; Tsai, M; Xie, J; Zhao, Z | 1 |
| Bakris, GL; Bergenstal, RM; Cannon, CP; Cushman, WC; Gourlie, NM; Heller, SR; Kupfer, S; Liu, Y; Mehta, CR; Nissen, SE; White, WB; Wilson, CA; Zannad, F | 1 |
| Huang, CN; Ji, L; Kadir, AA; Kim, DJ; Kuang, J; Lee, D; Li, L; Yang, T | 1 |
| Bertol, CD; Carlos, G; Friedrich, MT; Froehlich, PE | 1 |
| Kumagai, H; Matsubara, H; Oda, T; Oshima, N; Sakurai, Y; Takechi, H; Uchida, T; Watanabe, A | 1 |
| Bergmark, BA; Bonaca, MP; Cannon, CP; Jarolim, P; Liu, Y; Morrow, DA; White, WB; Zannad, F | 1 |
| Bakris, GL; Cannon, CP; Cavender, MA; Cushman, WC; Gao, Q; Jarolim, P; Kupfer, S; Mehta, CR; Morrow, DA; White, WB; Zannad, F | 1 |
| Aoki, C; Aso, Y; Kasai, K; Kuroda, H; Sagara, M; Shimizu, M; Suzuki, K | 1 |
| Goricar, K; Janez, A; Jensterle, M | 1 |
| Lingvay, I | 1 |
| Jiang, N; Li, G; Li, J; Liang, X; Liu, T; Qiu, J; Tse, G; Wang, X; Yang, Y; Zhang, X; Zhang, Z; Zhao, Y | 1 |
| Ayoub, BM; Hassan, MA; Mowaka, S; Zaghary, WA | 1 |
| Kaneko, M; Narukawa, M | 1 |
| Baba, S; Higashi, K; Iwasa, M; Kanamori, H; Kawasaki, M; Minatoguchi, S; Nishigaki, K; Yamada, Y | 1 |
| Arao, T; Kobayashi, T; Kurozumi, A; Masuda, D; Okada, Y; Tanaka, Y; Yamashita, S | 1 |
| Abeni, D; Collina, MC; Di Zenzo, G; Didona, B; Fania, L; Mazzanti, C; Pagnanelli, G; Provini, A; Salemme, A | 1 |
| Bakris, GL; Bergenstal, R; Cannon, CP; Cushman, W; Heller, S; Hwang, YC; Liu, Y; Mehta, C; Morrow, DA; White, WB; Zannad, F | 1 |
| Kabel, AM | 1 |
| Allakonda, L; Paul, D; Sahu, A; Satheeshkumar, N; Surendran, S | 1 |
| Amano, Y; Enya, K; Imai, M; Isono, O; Koumura, E; Matsukawa, J; Nagabukuro, H; Tohyama, K; Tsuchiya, S; Yasuno, H | 1 |
| Ayoub, BM; Mowaka, S | 1 |
| Abdel-Aziz, O; Ayoub, BM | 1 |
| Ishihara, S; Ishimura, N; Kinoshita, Y; Mishiro, T; Sato, S; Tobita, H; Yazaki, T | 1 |
| Greco, EL; Greco, G; Negro, R | 1 |
| Bergenstal, RM; Cannon, CP; Heller, SR; Howitt, H; Khunti, K; White, WB | 1 |
| Bergenstal, RM; Cannon, CP; Cavender, MA; Cushman, WC; Heller, S; Liu, Y; Massaro, JM; Mehta, CR; White, WB; Zannad, F | 1 |
| Alexander, GC; Baksh, SN; McAdams-DeMarco, M; Segal, JB | 1 |
| Bakris, GL; Cannon, CP; Cushman, WC; Liu, Y; Sharma, A; White, WB; Zannad, F | 1 |
| Hu, P; Jiang, J; Liu, D; Liu, H; Liu, Y; Ma, X; Shi, C; Song, L; Wu, Y; Yao, X; Zhao, Q; Zhou, H | 1 |
| Lamie, NT; Mahrouse, MA | 1 |
| Bandaru, SSM; Bhilare, S; Kapdi, AR; Sanghvi, YS; Schulzke, C | 1 |
| Katakami, N; Maeno, Y; Matsuoka, TA; Shimomura, I; Shiraiwa, T; Shiraiwa, Y; Takahara, M; Yamamoto, K; Yoshida, Y | 1 |
| Sano, M | 1 |
| Bakris, GL; Bergenstal, R; Cannon, CP; Cushman, WC; Heller, SR; Jalil, F; Liu, Y; Mehta, C; White, WB; Zannad, F | 1 |
| El-Yamany, MF; Rastanawi, AA; Saad, MA | 1 |
| Guo, AH; Han, XF; Hao, FL; Lu, XJ; Wang, XL; Zhao, XF; Zhao, ZR | 1 |
| Ding, Y; He, M; Li, Y; Mei, W; Meng, B; Xiang, G; Zhao, H; Zhu, B | 1 |
| Jiang, N; Li, G; Liu, C; Liu, R; Liu, T; Qiu, J; Suo, Y; Tse, G; Yang, Y; Zhang, X; Zhang, Z; Zhao, Y | 1 |
| Chen, L; Dong, J; Guo, B; Li, H; Li, Y; Liang, M; Liu, M; Mei, W; Wang, L; Xiang, G; Xiang, L; Zhang, J; Zhu, B | 1 |
| Chen, Y; Du, H; Zhang, P; Zhao, H | 1 |
| Cui, S; Field, RA; Li, J; Sun, D; Wang, G; Zang, Y; Zhang, H | 1 |
| Tang, X; Wang, Y; Yi, L | 1 |
| Fujiwara, S; Higashiyama, M; Miura, H; Suzuki, S; Takata, Y; Tanaka, A | 1 |
| Chayama, K; Goto, C; Hashimoto, H; Higashi, Y; Kajikawa, M; Kihara, Y; Kinoshita, Y; Kishimoto, S; Maruhashi, T; Matsui, S; Matsumoto, T; Mohamad Yusoff, F; Nakashima, A; Noma, K; Takaeko, Y | 1 |
| Hu, J; Li, J; Tan, X; Wang, H; Wang, J; Yang, C; Zhang, B; Zhao, Y | 1 |
| Itoh, H; Matsui, S; Meguro, S | 1 |
| Koike, Y; Miyata, K; Nishimura, R; Osonoi, T; Shimasaki, Y | 1 |
| Badran, OM; Elghobashy, MR; Kelani, KM; Rezk, MR | 1 |
| Aref, HA; Darwish, KM; Elgawish, MS; Hammad, SF | 1 |
| Cheng, CY; Chiang, CP; Chien, WC; Chung, CH; Hung, CT; Liu, JS; Wang, WM | 1 |
| Bakris, GL; Cannon, CP; Ferreira, JP; Liu, Y; Sharma, A; Vaduganathan, M; White, WB; Zannad, F | 1 |
| Dicembrini, I; Mannucci, E; Monami, M; Montereggi, C; Nreu, B | 1 |
| Akimoto, H; Asai, S; Nakayama, T; Nishida, Y; Takahashi, Y; Tezuka, K | 1 |
| Egashira, N; Hiromoto, S; Kawashiri, T; Kobayashi, D; Mine, K; Shigematsu, N; Shimazoe, T; Shimizu, S; Uchida, M | 1 |
| Derayea, SM; Gahlan, AA; Haredy, AM; Omar, MA; Saleh, GA | 1 |
| Hawley, I; Rahmani, MJ; Shahbaz, M; Zafar, M | 1 |
| Bakris, G; Ferreira, JP; Mehta, C; Rossignol, P; Sharma, A; White, WB; Zannad, F | 1 |
| Akhtar, M; Akhter, M; Kaundal, M; Najmi, AK; Panda, BP; Parvez, S; Rahman, SO; Salman, M; Shrivastava, A | 1 |
| Abdelhakeem, JI; ElGamal, MA; Nasr, MM; Roshdy, OK; Salama, RM | 1 |
| Fan, SH; Shi, YW; Wang, L; Xiong, QF; Zhang, LH | 1 |
| Bakris, G; Elharram, M; Ferreira, JP; Mehta, C; Rossignol, P; Sharma, A; White, W; Zannad, F | 1 |
| Gan, R; Li, H; Sun, Q; Xiang, H; Xiang, X; Zhang, S; Zhao, G; Zhao, L | 1 |
| Ahmed, LA; El Sayed, NS; El-Sahar, AE; Shiha, NA | 1 |
| Ali, NW; Elgebaly, AM; Farid, NF; Magdy, MA; Taha, AA | 1 |
| Hardman, TC; Hucke, O; Klein, T; Nar, H; Schnapp, G | 1 |
| Kachko, VA; Shestakova, EA; Shestakova, MV | 1 |
| Abiko, A; Araki, E; Fujimoto, S; Fujiwara, M; Hayashi, M; Inagaki, N; Kadowaki, T; Katagiri, H; Miyoshi, H; Nakamura, J; Naruse, K; Nishimura, R; Okada, Y; Shikata, K; Shimada, A; Shimomura, I; Tanizawa, Y; Ueki, K; Watada, H; Yamada, Y; Yamazaki, T | 1 |
| Abd Elmaaboud, MA; Arab, HH; Kabel, AM | 1 |
| Abe, M; Ishii, M; Kikuchi, T; Morimoto, K; Ogihara, T; Oikawa, E; Sasaki, M; Tomita, M | 1 |
| Fan, S; Niu, Y; Qin, J; Shi, Y; Wang, J; Xiong, Q; Zhang, L; Zhang, X | 1 |
| Cai, ZJ; Chen, T; Li, N; Lin, WQ; Liu, MB; Zheng, B | 1 |
| Bakris, G; Ferreira, JP; Mehta, C; Rossignol, P; White, WB; Zannad, F | 1 |
| Chan, P; Lam, CWK; Tomlinson, B | 1 |
| Hu, P; Li, H; Liu, D; Liu, H; Liu, X; Liu, Y; Xiao, X; Yang, J | 1 |
| Abdelkader, NF; Kortam, MA; Mohamed, AF; Ramadan, E; Safar, MM | 1 |
| Al-Sabti, B; Harbali, J | 1 |
| Gahlan, AA; Haredy, AM; Taher, MA; Tammam, AS | 1 |
| Abdullah, DM; Alsemeh, AE | 1 |
| Gao, B; Gao, W; Ji, Q; Wan, H; Xu, F; Zhang, X; Zhou, R | 1 |
| Choi, SH; Chun, SW; Hur, KY; Jeong, IK; Kang, ES; Kim, HJ; Kim, SK; Noh, JH; Rhee, EJ | 1 |
| Guo, N; Li, N; Liu, K; Sun, H; Zhao, Y | 1 |
| Nanjappan, SK; Ravichandiran, V; Somabattini, RA | 1 |
| Ahmad, W; Ahmed, MM; Bakshi, V; Eltayib, EM; Gilani, SJ; Imam, SS; Jahangir, MA; Kumar, LA; Mohanty, D; Zafar, A | 1 |
Reviews
55 review(s) available for uracil and piperidines
| Article | Year |
|---|---|
[Physiological aspects of endurance during muscular activity].
Topics: Adenosine Triphosphate; Amphetamine; Brain; Fatigue; Humans; Mitochondria, Muscle; Muscles; Myocardium; Oxygen Consumption; Phosphocreatine; Physical Education and Training; Physical Exertion; Piperidines; Uracil; Vitamin B Complex | 1970 |
Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Drug Interactions; Humans; Hypoglycemic Agents; Molecular Structure; Patents as Topic; Piperidines; Structure-Activity Relationship; Treatment Outcome; Uracil | 2008 |
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV.
Topics: Adamantane; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Nitriles; Piperidines; Pyrrolidines; Uracil; Vildagliptin | 2008 |
Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Piperidines; Sulfonylurea Compounds; Thiazolidinediones; Uracil | 2009 |
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.
Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Pioglitazone; Piperidines; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Uracil | 2009 |
The physiologic role of incretin hormones: clinical applications.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Incretins; Piperidines; Pyrazines; Sitagliptin Phosphate; Triazoles; Uracil | 2010 |
Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Obesity; Patient Compliance; Peptides; Piperidines; Precision Medicine; Primary Health Care; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2010 |
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
DPP-4 inhibitors: what may be the clinical differentiators?
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.
Topics: Animals; Cardiovascular System; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Incretins; Insulin Resistance; Lipid Metabolism; Liver; Mice; Pioglitazone; Piperidines; Rats; Thiazolidinediones; Uracil | 2010 |
Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus.
Topics: Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Humans; Incretins; Insulin-Secreting Cells; Piperidines; Structure-Activity Relationship; Uracil | 2010 |
Alogliptin: a review of its use in the management of type 2 diabetes mellitus.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Piperidines; Uracil | 2010 |
[Pharmacological and clinical profile of alogliptin benzoate (NESINA®)].
Topics: Adult; Animals; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Design; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Piperidines; Rats; Uracil | 2011 |
Alogliptin for the treatment of type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Interactions; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Piperidines; Treatment Outcome; Uracil | 2011 |
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin | 2011 |
Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.
Topics: Administration, Oral; Animals; Boronic Acids; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Humans; Hypoglycemic Agents; Linagliptin; Piperidines; Purines; Quinazolines; Uracil | 2011 |
[Alogliptin].
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Piperidines; Uracil | 2011 |
[A compounding agent of alogliptin and pioglitazone].
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Humans; Hypoglycemic Agents; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2011 |
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Topics: Adamantane; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain | 2012 |
Alogliptin benzoate for the treatment of type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Piperidines; Randomized Controlled Trials as Topic; Uracil | 2012 |
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon-Like Peptide 1; Humans; Linagliptin; Male; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin.
Topics: Animals; Clinical Trials as Topic; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Models, Molecular; Piperidines; Uracil | 2012 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2013 |
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.
Topics: Adult; Aged; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Molecular Targeted Therapy; Piperidines; Uracil | 2013 |
Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Piperidines; Treatment Outcome; Uracil | 2013 |
Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2014 |
Alogliptin: safety, efficacy, and clinical implications.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Piperidines; Randomized Controlled Trials as Topic; Uracil | 2015 |
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss | 2014 |
Alogliptin benzoate for the treatment of type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglycemic Agents; Piperidines; Uracil | 2014 |
Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.
Topics: Adamantane; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glycated Hemoglobin; Humans; Piperidines; Renal Insufficiency; Risk Factors; Treatment Outcome; Uracil | 2014 |
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Piperidones; Purines; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Thiazolidines; Triazoles; Uracil; Vildagliptin | 2014 |
Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Piperidines; Uracil | 2014 |
Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Hospitalization; Humans; Nitriles; Piperidines; Pyrrolidines; Sitagliptin Phosphate; Uracil; Vildagliptin | 2014 |
Emerging options for the treatment of type 2 diabetes in Chinese patients: focus on arterial function and alogliptin.
Topics: Animals; Arteries; Asian People; China; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Piperidines; Risk Factors; Treatment Outcome; Uracil; Vascular Stiffness | 2015 |
Risk of myocardial infarction in trials with Dipeptidyl Peptidase-4 inhibitors: Is duration of study a real issue?
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incidence; Myocardial Infarction; Patient Outcome Assessment; Patient Selection; Piperidines; Research Design; Time Factors; Uracil | 2015 |
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
Topics: Adamantane; Animals; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incretins; Piperidines; Protective Factors; Risk Assessment; Risk Factors; Treatment Outcome; Uracil | 2015 |
Alogliptin: a review of its use in patients with type 2 diabetes mellitus.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Piperidines; Randomized Controlled Trials as Topic; Uracil | 2015 |
Alogliptin benzoate for management of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Piperidines; Treatment Outcome; Uracil | 2015 |
Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Humans; Hypoglycemic Agents; Insulin; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2015 |
An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Piperidines; Uracil | 2015 |
Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective.
Topics: Adamantane; Cardiovascular System; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Piperidines; Sitagliptin Phosphate; Treatment Outcome; Uracil | 2015 |
First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus.
Topics: Asian People; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Japan; Piperidines; Uracil | 2015 |
Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation.
Topics: Aged; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Piperidines; Uracil | 2016 |
[The TECOS, EXAMINE and SAVOR studies--how do they differ and what are their outcomes?].
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Piperidines; Sitagliptin Phosphate; Uracil | 2015 |
Cardiovascular Effects of Incretin-Based Therapies.
Topics: Adamantane; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Heart Failure; Humans; Hypoglycemic Agents; Incretins; Piperidines; Sitagliptin Phosphate; Uracil | 2016 |
DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
Topics: Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Endpoint Determination; Humans; Hypoglycemic Agents; Linagliptin; Meta-Analysis as Topic; Observational Studies as Topic; Piperidines; Randomized Controlled Trials as Topic; Risk Factors; Sitagliptin Phosphate; Uracil | 2016 |
[Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials].
Topics: Adamantane; Cardiovascular System; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Heart Failure; Humans; Hypoglycemic Agents; Incretins; Peptides; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Uracil | 2016 |
Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes.
Topics: Acute Disease; Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incidence; Pancreatitis; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Uracil | 2017 |
Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Meta-Analysis as Topic; Peptides; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Uracil | 2017 |
SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Metformin; Piperidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uracil | 2017 |
Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Piperidines; Quality of Life; Sitagliptin Phosphate; Uracil | 2019 |
An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes.
Topics: Benzoates; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Half-Life; Humans; Hypoglycemia; Hypoglycemic Agents; Piperidines; Uracil | 2019 |
Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incidence; Neoplasms; Piperidines; Randomized Controlled Trials as Topic; Risk Factors; Sitagliptin Phosphate; Uracil; Vildagliptin | 2020 |
Trials
79 trial(s) available for uracil and piperidines
| Article | Year |
|---|---|
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fructosamine; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged; Piperidines; Placebos; Time Factors; Treatment Outcome; Uracil | 2008 |
Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Topics: Adolescent; Adult; Area Under Curve; Chromatography, High Pressure Liquid; Cohort Studies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Male; Middle Aged; Molecular Structure; No-Observed-Adverse-Effect Level; Piperidines; Reference Values; Tandem Mass Spectrometry; Time Factors; Uracil | 2008 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Uracil | 2008 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Sulfonylurea Compounds; Uracil; Young Adult | 2009 |
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Treatment Outcome; Uracil | 2009 |
Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.
Topics: Adolescent; Adult; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2009 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Piperidines; Placebos; Thiazolidinediones; Uracil; Young Adult | 2009 |
Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Piperidines; Treatment Outcome; Uracil; Weight Gain; Young Adult | 2009 |
Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.
Topics: Administration, Oral; Adult; Area Under Curve; Cimetidine; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Food-Drug Interactions; Histamine H2 Antagonists; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Uracil; Young Adult | 2010 |
Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pioglitazone; Piperidines; Thiazolidinediones; Treatment Outcome; Uracil | 2010 |
Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.
Topics: Asian People; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Exercise; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Piperidines; Thiazolidinediones; Treatment Outcome; Uracil | 2011 |
Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Maximum Tolerated Dose; Metformin; Middle Aged; Pioglitazone; Piperidines; Thiazolidinediones; Treatment Outcome; Uracil | 2011 |
Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study.
Topics: Aged; Algorithms; Asian People; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Placebos; Time Factors; Treatment Outcome; Uracil | 2011 |
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients wi
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Piperidines; Prospective Studies; Treatment Outcome; Uracil | 2011 |
Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Piperidines; Time Factors; Uracil | 2011 |
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Topics: Adamantane; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Pioglitazone; Piperidines; Postprandial Period; Thiazolidinediones; Treatment Outcome; Uracil | 2012 |
Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial.
Topics: Adult; Diabetes Mellitus, Type 2; Diet, Diabetic; Diet, Fat-Restricted; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Hospitals, Municipal; Humans; Hyperglycemia; Hyperlipidemias; Hypoglycemia; Insulin Resistance; Japan; Male; Middle Aged; Outpatient Clinics, Hospital; Patient Dropouts; Piperidines; Uracil; Weight Loss | 2012 |
Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2012 |
Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Medication Adherence; Metformin; Middle Aged; Pioglitazone; Piperidines; Thiazolidinediones; Treatment Outcome; Uracil | 2012 |
Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin.
Topics: Acarbose; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Enzyme Inhibitors; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemia; Insulin; Insulin Secretion; Islets of Langerhans; Male; Middle Aged; Overweight; Piperidines; Uracil; Weight Gain | 2013 |
The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Male; Piperidines; Prospective Studies; Renal Dialysis; Serum Albumin; Uracil | 2013 |
Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report.
Topics: Adult; Cross-Over Studies; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Postprandial Period; Uracil | 2013 |
Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Humans; Incidence; Male; Middle Aged; Piperidines; Proportional Hazards Models; Severity of Illness Index; Uracil | 2013 |
Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inositol; Japan; Linear Models; Male; Middle Aged; Piperidines; Prospective Studies; Pyrazines; Regional Blood Flow; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Uracil; Vasodilation | 2013 |
Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dizziness; Double-Blind Method; Female; Glipizide; Glycated Hemoglobin; Headache; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Piperidines; Prospective Studies; Treatment Outcome; Triglycerides; Uracil; Weight Gain | 2013 |
Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α-glucosidase inhibitors.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Prospective Studies; Serum Albumin; Time Factors; Treatment Outcome; Uracil | 2013 |
Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study.
Topics: Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypoglycemic Agents; Japan; Longitudinal Studies; Male; Middle Aged; Piperidines; Prevalence; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; Uracil | 2013 |
Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Piperidines; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Uracil | 2013 |
Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
Topics: Aged; Atherosclerosis; Diabetes Complications; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Piperidines; Uracil | 2013 |
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
Topics: Aged; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Piperidines; Uracil | 2013 |
DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Chemokine CXCL12; Cross-Over Studies; Cyclic AMP; Deoxyguanosine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Piperidines; Pyrazines; Receptor, Angiotensin, Type 1; Sitagliptin Phosphate; Triazoles; Up-Regulation; Uracil | 2014 |
Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Treatment Outcome; Uracil | 2014 |
The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Middle Aged; Pioglitazone; Piperidines; Thiazolidinediones; Treatment Outcome; Uracil | 2014 |
[The design and baseline characteristics of a phase III study to evaluate the efficacy and safety of alogliptin versus placebo in type 2 diabetes mellitus in Mainland China].
Topics: Adult; China; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Prospective Studies; Research Design; Treatment Outcome; Uracil | 2013 |
Efficacy of adding once- and thrice-daily voglibose in Japanese type 2 diabetic patients treated with alogliptin.
Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Piperidines; Treatment Outcome; Uracil | 2014 |
[The EXAMINE study].
Topics: Administration, Oral; Angina, Unstable; Biomarkers; Diabetes Mellitus, Type 2; Double-Blind Method; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Myocardial Infarction; Piperidines; Practice Guidelines as Topic; Research Design; Risk Factors; Treatment Outcome; Uracil | 2014 |
Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pancreatitis; Piperidines; Treatment Outcome; Uracil | 2014 |
Effect of combination therapy with alogliptin and lansoprazole on glycemic control in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lansoprazole; Male; Middle Aged; Piperidines; Treatment Outcome; Uracil | 2014 |
Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Piperidines; Placebo Effect; Uracil; Weight Gain | 2014 |
Alogliptin: a new dipeptidyl peptidase-4 inhibitor with potential anti-atherogenic properties.
Topics: Adult; Aged; Atherosclerosis; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Insulin Resistance; Insulin-Secreting Cells; Lipids; Male; Middle Aged; Piperidines; Uracil | 2015 |
Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study.
Topics: Administration, Oral; Asian People; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Glycated Hemoglobin; Humans; Piperidines; Uracil | 2015 |
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Piperidines; Risk Factors; Stroke; Uracil | 2015 |
The Beneficial Effects of the DPP-4 Inhibitor Alogliptin on Hemoglobin A1c and Serum Lipids in Japanese Patients with Type 2 Diabetes.
Topics: Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Piperidines; Sitagliptin Phosphate; Uracil | 2016 |
Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, parallel-group, comparative study.
Topics: Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Exercise; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Japan; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2015 |
Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
Topics: Aged; Atherosclerosis; Blood Glucose; Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Piperidines; Prospective Studies; Uracil | 2016 |
[Efficacy and safety of alogliptin in treatment of type 2 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial in mainland China].
Topics: Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Pioglitazone; Piperidines; Safety; Thiazolidinediones; Uracil | 2015 |
Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Endpoint Determination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Treatment Outcome; Uracil; Weight Gain; Young Adult | 2016 |
Ipragliflozin as an Initial Therapy in Drug Naïve Subjects with Type 2 Diabetes.
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Prospective Studies; Thiophenes; Uracil | 2016 |
Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.
Topics: Adult; Aged; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Hong Kong; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Piperidines; Taiwan; Thiazolidinediones; Treatment Outcome; Uracil | 2017 |
Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care tria
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Female; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Outcome and Process Assessment, Health Care; Piperidines; Risk Assessment; Standard of Care; Stroke; Uracil | 2016 |
Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Multivariate Analysis; Piperidines; Proportional Hazards Models; Risk; Uracil | 2016 |
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
Topics: Acute Coronary Syndrome; Aged; Angiotensin-Converting Enzyme Inhibitors; Confidence Intervals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Prognosis; Proportional Hazards Models; Prospective Studies; Reference Values; Risk Assessment; Survival Rate; Treatment Outcome; Uracil | 2016 |
Inhibition of DPP-4 by alogliptin improves coronary flow reserve and left ventricular systolic function evaluated by phase contrast cine magnetic resonance imaging in patients with type 2 diabetes and coronary artery disease.
Topics: Aged; Aged, 80 and over; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Fractional Flow Reserve, Myocardial; Humans; Magnetic Resonance Imaging, Cine; Male; Piperidines; Prospective Studies; Uracil; Ventricular Function, Left | 2016 |
Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose; Glycated Hemoglobin; Humans; Male; Middle Aged; Nitriles; Piperidines; Pyrrolidines; Treatment Outcome; Uracil; Vildagliptin | 2017 |
Randomized, double-blind, phase III study to evaluate the efficacy and safety of once-daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes.
Topics: Acute Disease; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Nasopharyngitis; Pancreatitis; Piperidines; Treatment Outcome; Uracil | 2017 |
The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Area Under Curve; Child; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Half-Life; Humans; Hypoglycemic Agents; Male; Piperidines; Uracil; Young Adult | 2017 |
Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
Topics: Acute Coronary Syndrome; Cardiovascular Diseases; Cohort Studies; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Middle Aged; Piperidines; Risk Factors; Secondary Prevention; Severity of Illness Index; Uracil | 2017 |
Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial.
Topics: China; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exercise; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Immunity, Mucosal; Incidence; Malaysia; Metformin; Middle Aged; Piperidines; Republic of Korea; Respiratory Tract Infections; Taiwan; Uracil | 2017 |
Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial.
Topics: Acute Coronary Syndrome; Adiponectin; Aged; Biomarkers; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Middle Aged; Mortality; Piperidines; Proportional Hazards Models; Risk; Secondary Prevention; Uracil | 2017 |
Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Standard of Care; Treatment Outcome; Troponin I; Uracil | 2017 |
Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index.
Topics: Aged; Alanine Transaminase; Blood Glucose; Body Mass Index; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; gamma-Glutamyltransferase; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Piperidines; Uracil | 2017 |
Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS.
Topics: Adult; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Meals; Metformin; Obesity; Pioglitazone; Piperidines; Polycystic Ovary Syndrome; Prediabetic State; Prevalence; Slovenia; Thiazolidinediones; Uracil | 2017 |
Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients.
Topics: Aged; Apolipoprotein B-100; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Lipid Metabolism; Lipids; Male; Piperidines; Pyrimidines; Treatment Outcome; Uracil | 2018 |
High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.
Topics: Acute Coronary Syndrome; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Piperidines; Standard of Care; Treatment Outcome; Uracil | 2018 |
Alogliptin and Gliclazide Similarly Increase Circulating Endothelial Progenitor Cells in Type 2 Diabetes Patients.
Topics: Aged; Diabetes Mellitus, Type 2; Endothelial Progenitor Cells; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Uracil | 2019 |
Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Sulfonylurea Compounds; Treatment Outcome; Uracil | 2018 |
Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Piperidines; Stroke; Survival Rate; Treatment Outcome; United States; Uracil | 2018 |
Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Piperidines; Recurrence; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Uracil | 2018 |
Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial.
Topics: Aged; Analysis of Variance; Blood Pressure Determination; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Myocardial Ischemia; Piperidines; Prognosis; Prospective Studies; United States; Uracil | 2018 |
Treatment preference for weekly versus daily DPP-4 inhibitors in patients with type 2 diabetes mellitus: outcomes from the TRINITY trial.
Topics: Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Patient Preference; Physician-Patient Relations; Piperidines; Practice Patterns, Physicians'; Surveys and Questionnaires; Uracil | 2019 |
A Randomized Pilot Study of the Effect of Trelagliptin and Alogliptin on Glycemic Variability in Patients with Type 2 Diabetes.
Topics: Aged; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Pilot Projects; Piperidines; Uracil | 2019 |
Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Blood Proteins; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Galectin 3; Galectins; Growth Differentiation Factor 15; Heart Disease Risk Factors; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Piperidines; Prognosis; Risk Assessment; Troponin I; Uracil | 2020 |
Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial.
Topics: Biomarkers; Cause of Death; Comorbidity; Diabetes Mellitus, Type 2; Female; Fibroblast Growth Factor-23; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Piperidines; Prognosis; Proteomics; Risk Assessment; Survival Rate; Uracil | 2021 |
Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus.
Topics: Acute Coronary Syndrome; Comorbidity; Diabetes Mellitus, Type 2; Evidence-Based Practice; Female; Heart Disease Risk Factors; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Patient Selection; Piperidines; Random Allocation; Risk Assessment; Stroke; Time Factors; Uracil | 2020 |
Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; C-Peptide; China; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Imidazoles; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Piperidines; Pyridines; Treatment Outcome; Uracil; Young Adult | 2021 |
Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomi
Topics: Acarbose; Adult; Aspirin; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Glycated Hemoglobin; Heart Disease Risk Factors; Humans; Hypoglycemic Agents; Metformin; Piperidines; Prospective Studies; Treatment Outcome; Uracil | 2022 |
Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study.
Topics: Autoimmune Diseases; Blood Glucose; Blood Glucose Self-Monitoring; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Lipoproteins, HDL; Metformin; Pioglitazone; Piperidines; Sulfonylurea Compounds; Treatment Outcome; Uracil | 2022 |
Effects of Systematic Diet Education Combined with Multidisciplinary Nursing on Nutritional Status and Calcium and Phosphorus Metabolism in Patients with Diabetic Kidney Disease in Uremic Phase after Treatment with Alogliptin.
Topics: Calcium; Diabetes Mellitus; Diabetic Nephropathies; Diet; Female; Humans; Male; Nutritional Status; Phosphorus; Piperidines; Uracil | 2022 |
Other Studies
152 other study(ies) available for uracil and piperidines
| Article | Year |
|---|---|
Electrostatic effects in the interaction of polyuridylic acid with N-(2,2,6,6-tetramethyl-1-oxylpiperidin-4-yl)-N'-(beta-(4-methylmorpholinio) ethyl)-carbodiimide.
Topics: Binding Sites; Carbodiimides; Carbon Radioisotopes; Cyclic N-Oxides; Kinetics; Mathematics; Morpholines; Nucleic Acid Conformation; Osmolar Concentration; Piperidines; Poly U; Sodium Chloride; Temperature; Time Factors; Uracil; Urea; Uridine | 1974 |
[On some new piperidinomethyl derivatives of substances with a replaceable hydrogen].
Topics: Barbiturates; Hydrogen; Malonates; Piperidines; Uracil | 1961 |
Optimization and kinetic model of condensation of a secondary amine with a uracil derivative in the synthesis of 2-[(1-carbethoxy-4-piperidinyl) (methyl)amino]-1H-pyrimidin-4-one.
Topics: Algorithms; Chemical Phenomena; Chemistry, Physical; Kinetics; Models, Chemical; Piperidines; Pyrimidinones; Uracil | 2004 |
Estimation of pK(a) values using microchip capillary electrophoresis and indirect fluorescence detection.
Topics: Aniline Compounds; Chemical Phenomena; Chemistry, Physical; Cimetidine; Electrophoresis, Microchip; Ethosuximide; Fluorescence; Fluorescent Dyes; Hydrogen-Ion Concentration; Piperidines; Prilocaine; Procaine; Pyridines; Ranitidine; Reproducibility of Results; Rhodamines; Sulfanilamide; Sulfanilamides; Uracil | 2005 |
Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.
Topics: Animals; Binding Sites; Blood Glucose; Cytochrome P-450 Enzyme Inhibitors; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dogs; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Female; Glucose Tolerance Test; Haplorhini; Humans; Hypoglycemic Agents; In Vitro Techniques; Mice; Microsomes, Liver; Models, Molecular; Piperidines; Pyrimidinones; Quinazolinones; Rats; Rats, Wistar; Structure-Activity Relationship; Uracil | 2007 |
Methylation and uracil interference assays for analysis of protein-DNA interactions.
Topics: Animals; Autoradiography; Binding Sites; DNA; DNA Methylation; DNA Probes; DNA-Binding Proteins; Electrophoresis, Polyacrylamide Gel; Electrophoretic Mobility Shift Assay; Humans; Piperidines; Polymerase Chain Reaction; Protein Binding; Uracil; Uracil-DNA Glycosidase | 2001 |
Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glucagon; Glucagon-Like Peptide 1; Insulin; Male; Mice; Mice, Obese; Piperidines; Triglycerides; Uracil | 2008 |
Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
Topics: Administration, Oral; Animals; Biological Availability; Blood Glucose; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Administration Schedule; Glucagon-Like Peptide 1; Glucose Metabolism Disorders; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Macaca fascicularis; Male; Piperidines; Rats; Rats, Sprague-Dawley; Rats, Zucker; Uracil | 2008 |
The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice.
Topics: Animals; Blood Glucose; Body Weight; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Eating; Enzyme Inhibitors; Hormones; Hyperinsulinism; Insulin; Lipids; Male; Mice; Mice, Obese; Pancreas; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2009 |
Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
Topics: Adiponectin; Animals; Blood Glucose; Body Weight; Cell Degranulation; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Eating; Glucagon; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Lipids; Male; Mice; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2009 |
A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Hypoglycemic Agents; Male; Piperidines; Rats; Sulfonylurea Compounds; Treatment Failure; Uracil | 2009 |
Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Randomized Controlled Trials as Topic; Treatment Outcome; Uracil; Young Adult | 2009 |
Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice.
Topics: Animals; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Hypoglycemic Agents; Inositol; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Piperidines; Prediabetic State; RNA-Binding Proteins; Transcription Factors; Uracil | 2010 |
DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes.
Topics: Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Humans; Lipopolysaccharides; Macrophages; Matrix Metalloproteinase 1; Matrix Metalloproteinase Inhibitors; Piperidines; Toll-Like Receptor 4; U937 Cells; Uracil | 2010 |
The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Drug Discovery; HEK293 Cells; Humans; Male; Piperidines; Pyrimidines; Rats; Uracil | 2011 |
Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Blood Glucose; Body Weight; Deoxyguanosine; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Insulin, Long-Acting; Maf Transcription Factors, Large; Mice; Mice, Inbred C57BL; Pioglitazone; Piperidines; Receptors, Glucagon; Thiazolidinediones; Triglycerides; Uracil | 2011 |
Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Insulin-Secreting Cells; Male; Mice; Mice, Obese; Piperidines; Prediabetic State; Streptozocin; Uracil | 2011 |
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Topics: Adamantane; Allylamine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Investigational New Drug Application; Liraglutide; Nitriles; Peptides; Piperidines; Practice Guidelines as Topic; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Triazoles; United States; United States Food and Drug Administration; Uracil; Venoms; Vildagliptin | 2011 |
DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Interleukin-1beta; Interleukin-6; Male; Mice; Mice, Knockout; Piperidines; Real-Time Polymerase Chain Reaction; Triglycerides; U937 Cells; Uracil | 2011 |
Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Diabetic Neuropathies; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Male; Motor Neurons; Neural Conduction; Oxidative Stress; Pain Measurement; Pain Threshold; Piperidines; Rats; Rats, Sprague-Dawley; Sensory Receptor Cells; Time Factors; Uracil; Vasodilation; Weight Gain | 2011 |
Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Blood Pressure; Cell Movement; Chemotaxis; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Glucose; Inflammation; Insulin Resistance; Male; Metabolism; Mice; Mice, Knockout; Monocytes; Piperidines; Receptors, LDL; Time Factors; Uracil | 2011 |
Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.
Topics: Animals; Area Under Curve; Cardiomyopathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Gene Expression Regulation; Glomerular Filtration Rate; Glucagon-Like Peptide 1; Heart; Humans; Kidney Failure, Chronic; Linagliptin; Myocardium; Natriuretic Peptide, Brain; Nephrectomy; Piperidines; Purines; Pyrazines; Quinazolines; Rats; Reverse Transcriptase Polymerase Chain Reaction; Sitagliptin Phosphate; Triazoles; Uracil; Uremia | 2011 |
Trifluoromethylation of arenes and heteroarenes by means of photoredox catalysis.
Topics: Anticholesteremic Agents; Atorvastatin; Catalysis; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Donepezil; Drug Design; Flavones; Halogenation; Heptanoic Acids; Indans; Isomerism; Light; Methylation; Molecular Structure; Oxidation-Reduction; Pharmaceutical Preparations; Photochemical Processes; Piperidines; Pyrroles; Uracil | 2011 |
[Therapeutic use and adverse events of incretin-related drugs].
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2012 |
Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Kidney; Mice; Mice, Knockout; Natriuresis; Natriuretic Agents; Obesity; Peptides; Phosphorylation; Piperidines; Receptors, Glucagon; Uracil; Venoms | 2012 |
Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?
Topics: Adamantane; Aged; Angioedema; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Substitution; Humans; Male; Nitriles; Piperidines; Pyrrolidines; Uracil; Vildagliptin | 2013 |
A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site.
Topics: Adamantane; Catalytic Domain; Crystallography, X-Ray; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Multiprotein Complexes; Nitriles; Oligopeptides; Piperidines; Protein Binding; Protein Interaction Mapping; Pyrazines; Pyrazoles; Pyrrolidines; Serine; Sitagliptin Phosphate; Structure-Activity Relationship; Thiazolidines; Triazoles; Uracil; Vildagliptin; X-Ray Diffraction | 2013 |
US FDA approves three new drugs for Type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Piperidines; United States; United States Food and Drug Administration; Uracil | 2013 |
Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice.
Topics: Analysis of Variance; Animals; Brain Edema; Brain Infarction; Brain Ischemia; Brain-Derived Neurotrophic Factor; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Laser-Doppler Flowmetry; Male; Mice; Mice, Inbred C57BL; Microcirculation; Nervous System Diseases; Piperidines; Prosencephalon; Time Factors; Uracil | 2013 |
Alogliptin (nesina) for type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Piperidines; Uracil | 2013 |
Alogliptin and its benzoate salt.
Topics: Benzoates; Crystallography, X-Ray; Hydrogen Bonding; Molecular Conformation; Molecular Structure; Piperidines; Uracil | 2013 |
Enhancing pancreatic Beta-cell regeneration in vivo with pioglitazone and alogliptin.
Topics: Animals; Cell Proliferation; Diabetes Mellitus, Experimental; Drug Synergism; Female; Gene Expression; Genes, Reporter; Hypoglycemic Agents; Immunosuppressive Agents; Insulin; Insulin-Secreting Cells; Luciferases; Luminescent Measurements; Male; Mice; Pioglitazone; Piperidines; Promoter Regions, Genetic; Regeneration; Sirolimus; Streptozocin; Tacrolimus; Thiazolidinediones; Uracil | 2013 |
Orally administered dipeptidyl peptidase-4 inhibitor (alogliptin) prevents abdominal aortic aneurysm formation through an antioxidant effect in rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Administration, Oral; Animals; Antioxidants; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Blood Glucose; Calcium Chloride; Deoxyguanosine; Dilatation, Pathologic; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; DNA Damage; Dose-Response Relationship, Drug; Gene Expression Regulation, Enzymologic; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Oxidative Stress; Pancreatic Elastase; Piperidines; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; RNA, Messenger; Time Factors; Uracil | 2014 |
Perivascular fibroblasts form the fibrotic scar after contusive spinal cord injury.
Topics: Analysis of Variance; Animals; Antigens; Blood Vessels; CD13 Antigens; Cell Count; Cicatrix; Collagen Type I; Collagen Type I, alpha 1 Chain; Disease Models, Animal; Disease Progression; Female; Fibroblasts; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Green Fluorescent Proteins; Lectins; Leukocyte Common Antigens; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pericytes; Piperidines; Proteoglycans; Receptor, Platelet-Derived Growth Factor beta; Spinal Cord Injuries; Time Factors; Uracil | 2013 |
Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.
Topics: Animals; Crystallography, X-Ray; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Activation; Inhibitory Concentration 50; Linagliptin; Male; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Piperidines; Purines; Quinazolines; Rats; Rats, Sprague-Dawley; Uracil | 2013 |
New oral hypoglycaemics fail to show cardiovascular benefits.
Topics: Adamantane; Cardiovascular Diseases; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Piperidines; Randomized Controlled Trials as Topic; Treatment Failure; Uracil | 2013 |
Diabetes: Cardiovascular safety of 'gliptin' therapy.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2013 |
Pharmacotherapy: Cardiovascular safety of antihyperglycaemic drugs in patients with type 2 diabetes mellitus.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2013 |
Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection.
Topics: Acute Kidney Injury; Animals; Antineoplastic Agents; Apoptosis; Cisplatin; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Intestinal Mucosa; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Peptides; Piperidines; Receptors, Glucagon; Reperfusion Injury; RNA, Small Interfering; Uracil; Venoms | 2013 |
New drugs improve glycemic control in type 2 diabetes, but improving heart health remains elusive.
Topics: Adamantane; Blood Glucose; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Drug Approval; Humans; Hypoglycemic Agents; Piperidines; Uracil | 2013 |
Dipeptidyl peptidase IV inhibitor lowers PPARγ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retention.
Topics: Adipocytes, Brown; Adipose Tissue, Brown; Animals; Body Weight; Dipeptidyl-Peptidase IV Inhibitors; Eating; Male; Mice; Pioglitazone; Piperidines; PPAR gamma; Thiazolidinediones; Uracil; Water-Electrolyte Balance | 2014 |
Pharmacoeconomic analysis of DPP-4 inhibitors.
Topics: Adamantane; Clinical Trials as Topic; Cohort Studies; Cost-Benefit Analysis; Costs and Cost Analysis; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
New drugs 2014, part 1.
Topics: Abatacept; Adult; Anticoagulants; Antidiarrheals; Antitubercular Agents; Benzazepines; Canagliflozin; Dimethyl Fumarate; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Dyspareunia; Humans; Hypoglycemic Agents; Multiple Sclerosis; Obesity; Oligonucleotides; Piperidines; Proanthocyanidins; Tamoxifen; Uracil | 2014 |
Saxagliptin, alogliptin, and cardiovascular outcomes.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2014 |
Saxagliptin, alogliptin, and cardiovascular outcomes.
Topics: Angina, Unstable; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2014 |
Effects of alogliptin in chronic kidney disease patients with type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome; Uracil | 2014 |
Relapsing 6q24-related transient neonatal diabetes mellitus successfully treated with a dipeptidyl peptidase-4 inhibitor: a case report.
Topics: Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Male; Piperidines; Recurrence; Treatment Outcome; Uracil; Young Adult | 2014 |
Separation of alogliptin enantiomers in cyclodextrin-modified capillary electrophoresis: a validated method.
Topics: Cyclodextrins; Dipeptidyl-Peptidase IV Inhibitors; Electrophoresis, Capillary; Limit of Detection; Linear Models; Piperidines; Reproducibility of Results; Stereoisomerism; Uracil | 2014 |
Characterization of process-related impurities including forced degradation products of alogliptin benzoate and the development of the corresponding reversed-phase high-performance liquid chromatography method.
Topics: Benzoates; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Stability; Molecular Structure; Piperidines; Uracil | 2014 |
Outcome results renew debate about diabetes drug development.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Drug Approval; Humans; Hypoglycemic Agents; Piperidines; Treatment Outcome; Uracil | 2013 |
Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Eating; Humans; Hypoglycemic Agents; Insulin; Male; Pioglitazone; Piperidines; Rats; Thiazolidinediones; Uracil | 2014 |
Gliptins - do they increase cardiovascular risk or benefit?
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2014 |
Alogliptin improves steroid-induced hyperglycemia in treatment-naïve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels.
Topics: Aged; Asian People; Body Mass Index; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Japan; Kidney Function Tests; Male; Piperidines; Regression Analysis; Renal Insufficiency, Chronic; Steroids; Uracil; Vital Signs | 2014 |
[A novel dipeptidyl peptidase IV inhibitors developed through scaffold hopping and drug splicing strategy].
Topics: Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Drug Discovery; Humans; Hypoglycemic Agents; Linagliptin; Molecular Structure; Piperidines; Structure-Activity Relationship; Uracil | 2014 |
Dipeptidyl peptidase-4 inhibitors and cardiovascular safety.
Topics: Adamantane; Blood Glucose; Cardiovascular Diseases; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Piperidines; Uracil | 2014 |
[New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2014 |
Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Humans; Linagliptin; Models, Molecular; Piperidines; Protein Conformation; Purines; Quinazolines; Structure-Activity Relationship; Substrate Specificity; Uracil | 2014 |
Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Observational Studies as Topic; Piperidines; Prospective Studies; Registries; Uracil | 2014 |
Once-weekly DPP-4 inhibitors: do they meet an unmet need?
Topics: Asian People; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Piperidines; Uracil | 2015 |
Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury.
Topics: Animals; Anti-Inflammatory Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antilymphocyte Serum; Cell Line; Chemokine CCL2; Chemotaxis; Cytoprotection; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Exenatide; Glomerulonephritis; Glucagon-Like Peptide-1 Receptor; Kidney Glomerulus; Macrophages, Peritoneal; Male; Mice, Inbred C57BL; Peptides; Piperidines; Proteinuria; Pyrimidines; Rats, Sprague-Dawley; Receptors, Glucagon; Signal Transduction; Uracil; Venoms | 2015 |
Dipeptidyl peptidase-4 inhibition in diabetic rats leads to activation of the transcription factor CREB in β-cells.
Topics: Animals; Baculoviral IAP Repeat-Containing 3 Protein; Blood Glucose; Cyclic AMP Response Element-Binding Protein; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Inhibitor of Apoptosis Proteins; Insulin; Insulin Receptor Substrate Proteins; Insulin-Secreting Cells; Male; Piperidines; Proto-Oncogene Proteins c-bcl-2; Rats, Zucker; Triglycerides; Uracil | 2015 |
An interaction between glucagon-like peptide-1 and adenosine contributes to cardioprotection of a dipeptidyl peptidase 4 inhibitor from myocardial ischemia-reperfusion injury.
Topics: Adenosine; Adenosine Deaminase; Animals; Apoptosis; Cardiotonic Agents; Cyclic AMP Response Element-Binding Protein; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Extracellular Signal-Regulated MAP Kinases; Female; Glucagon-Like Peptide 1; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hemodynamics; Myocardial Reperfusion Injury; Piperidines; Protein Binding; Proto-Oncogene Proteins c-akt; Purinergic P1 Receptor Antagonists; Theophylline; Uracil | 2015 |
Alogliptin, a dipeptidyl peptidase-4 inhibitor, regulates the atrial arrhythmogenic substrate in rabbits.
Topics: Animals; Atrial Fibrillation; Blotting, Western; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Echocardiography; Electrophysiology; Endothelium; Enzyme-Linked Immunosorbent Assay; Fibrosis; Fluorescent Antibody Technique; Heart Atria; Heart Failure; Male; Neovascularization, Physiologic; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Phosphorylation; Piperidines; Rabbits; Tachycardia, Ventricular; Uracil | 2015 |
DPP-4 inhibitors and risk of heart failure EXAMINEd.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Piperidines; Uracil | 2015 |
Dipeptidyl-peptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice.
Topics: Actins; Animals; Anti-Inflammatory Agents; Arteritis; Atherosclerosis; Biomarkers; Blood Glucose; Cell Proliferation; Chemokine CCL2; Cholesterol; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Femoral Artery; Glucagon-Like Peptide 1; Inflammation Mediators; Interleukin-1beta; Male; Mice, Knockout; Neointima; NF-kappa B; Phosphorylation; Piperidines; Proliferating Cell Nuclear Antigen; Receptors, LDL; Tumor Necrosis Factor-alpha; Uracil; Vascular System Injuries | 2015 |
Impact of alogliptin and pioglitazone on lipid metabolism in islets of prediabetic and diabetic Zucker Diabetic Fatty rats.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Islets of Langerhans; Lipid Metabolism; Male; Pioglitazone; Piperidines; Prediabetic State; Rats; Rats, Zucker; Thiazolidinediones; Uracil | 2015 |
[Fixed-dose combination].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Inositol; Isoindoles; Metformin; Pioglitazone; Piperidines; Sulfonylurea Compounds; Thiazolidinediones; Uracil | 2015 |
Combination of DPP-4 inhibitor and PPARγ agonist exerts protective effects on pancreatic β-cells in diabetic db/db mice through the augmentation of IRS-2 expression.
Topics: Animals; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Insulin Receptor Substrate Proteins; Insulin-Secreting Cells; Male; Mice; Pioglitazone; Piperidines; PPAR gamma; Thiazolidinediones; Uracil | 2015 |
Distinct glucose-lowering properties in good responders treated with sitagliptin and alogliptin.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Sitagliptin Phosphate; Uracil | 2015 |
Pharmacological stimulation of serotonin 5-HT1B receptors enhances increases in plasma active glucagon-like peptide-1 levels induced by dipeptidyl peptidase-4 inhibition independently of feeding in mice.
Topics: Administration, Oral; Animals; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Food-Drug Interactions; Glucagon-Like Peptide 1; Glucose Intolerance; Injections, Intraperitoneal; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Mice, Inbred C57BL; Piperazines; Piperidines; Pyridines; Receptor, Serotonin, 5-HT1B; Serotonin 5-HT1 Receptor Agonists; Up-Regulation; Uracil | 2015 |
Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes.
Topics: Aged; Albumins; Angiotensinogen; Biomarkers; Creatinine; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Japan; Kidney; Kidney Diseases; Logistic Models; Male; Middle Aged; Piperidines; Prognosis; Treatment Outcome; Uracil | 2015 |
EXAMINE: targeting risk and treatment in diabetes.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Piperidines; Uracil | 2015 |
EXAMINE: targeting risk and treatment in diabetes.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Piperidines; Uracil | 2015 |
EXAMINE: targeting risk and treatment in diabetes.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Piperidines; Uracil | 2015 |
EXAMINE: targeting risk and treatment in diabetes - Authors' reply.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Piperidines; Uracil | 2015 |
Mosapride, a selective serotonin 5-HT4 receptor agonist, and alogliptin, a selective dipeptidyl peptidase-4 inhibitor, exert synergic effects on plasma active GLP-1 levels and glucose tolerance in mice.
Topics: Animals; Benzamides; Blood Glucose; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Morpholines; Piperidines; Serotonin 5-HT4 Receptor Agonists; Uracil | 2015 |
Retrospective and Prospective Human Intravenous and Oral Pharmacokinetic Projection of Dipeptidyl peptidase-IV Inhibitors Using Simple Allometric Principles - Case Studies of ABT-279, ABT-341, Alogliptin, Carmegliptin, Sitagliptin and Vildagliptin.
Topics: Adamantane; Administration, Intravenous; Administration, Oral; Animals; Biphenyl Compounds; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Haplorhini; Humans; Nitriles; Piperidines; Prospective Studies; Pyridines; Pyrrolidines; Quinolizines; Rats; Retrospective Studies; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2015 |
Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptin.
Topics: Adolescent; Adult; Aged; Biological Availability; Body Weight; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hypoglycemic Agents; Kidney; Kidney Function Tests; Male; Middle Aged; Models, Biological; Piperidines; Tissue Distribution; Uracil; Young Adult | 2016 |
Dipeptidyl Peptidase 4 Inhibition Alleviates Shortage of Circulating Glucagon-Like Peptide-1 in Heart Failure and Mitigates Myocardial Remodeling and Apoptosis via the Exchange Protein Directly Activated by Cyclic AMP 1/Ras-Related Protein 1 Axis.
Topics: Animals; Apoptosis; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Glucagon-Like Peptide 1; Guanine Nucleotide Exchange Factors; Heart Failure; Male; Mice, Inbred C57BL; Myocytes, Cardiac; Peptide Fragments; Piperidines; Proto-Oncogene Proteins c-bcl-2; rap1 GTP-Binding Proteins; Signal Transduction; Uracil; Ventricular Remodeling | 2016 |
[In Process Citation].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Piperidines; Uracil | 2015 |
Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Angina, Unstable; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Peptides; Piperidines; Uracil | 2016 |
Methods for meta-analysis of pharmacodynamic dose-response data with application to multi-arm studies of alogliptin.
Topics: Biostatistics; Computer Simulation; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Models, Statistical; Network Meta-Analysis; Nonlinear Dynamics; Piperidines; Randomized Controlled Trials as Topic; Uracil | 2018 |
Glucagon-Like Peptide-1-Mediated Modulation of Inflammatory Pathways in the Diabetic Brain: Relevance to Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Blood Glucose; Body Weight; Brain; Cytokines; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Gene Expression Regulation; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Nerve Tissue Proteins; Nitric Oxide Synthase Type II; Oxidative Stress; Piperidines; Rats; Rats, Zucker; Signal Transduction; Transcriptome; Uracil | 2016 |
Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods.
Topics: Administration, Oral; Animals; Area Under Curve; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Female; Haplorhini; Humans; Imidazoles; Male; Piperidines; Pyridines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Uracil | 2016 |
Effects of alogliptin on fractional flow reserve evaluated by coronary computed tomography angiography in patients with type 2 diabetes: Rationale and design of the TRACT study.
Topics: Aged; Carotid Intima-Media Thickness; Computed Tomography Angiography; Coronary Angiography; Coronary Stenosis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Fractional Flow Reserve, Myocardial; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Piperidines; Plaque, Atherosclerotic; Prospective Studies; Uracil | 2017 |
Isolation and characterization of related substances in alogliptin benzoate by LC-QTOF mass spectrometric techniques.
Topics: Chromatography, High Pressure Liquid; Drug Compounding; Drug Stability; Hot Temperature; Hydrogen-Ion Concentration; Hypoglycemic Agents; Indicators and Reagents; Limit of Detection; Oxidation-Reduction; Photolysis; Piperidines; Reproducibility of Results; Tablets; Tandem Mass Spectrometry; Uracil | 2016 |
Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism.
Topics: Animals; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Humans; Male; Piperidines; Rats, Sprague-Dawley; Sitagliptin Phosphate; Substrate Specificity; Time Factors; Uracil | 2016 |
Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Humans; Hypoglycemic Agents; Piperidines; Risk Factors; Sitagliptin Phosphate; Uracil | 2016 |
Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice.
Topics: Adamantane; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; General Practice; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Nitriles; Piperidines; Pyrrolidines; Retrospective Studies; Sitagliptin Phosphate; Uracil; Vildagliptin | 2016 |
Dipeptidyl peptidase- IV inhibitor alogliptin improves stress-induced insulin resistance and prothrombotic state in a murine model.
Topics: Adipose Tissue; Animals; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Inflammation; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Piperidines; Stress, Psychological; Thrombophilia; Uracil | 2016 |
The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Lung; Male; Metformin; Middle Aged; Obesity; Piperidines; Respiratory Function Tests; Uracil | 2016 |
Degradation Kinetics Study of Alogliptin Benzoate in Alkaline Medium by Validated Stability-Indicating HPTLC Method.
Topics: Benzoates; Chromatography, High Pressure Liquid; Drug Stability; Kinetics; Piperidines; Sodium Hydroxide; Uracil | 2016 |
New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
Topics: Adamantane; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Peptides; Piperidines; Risk; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Uracil | 2016 |
Comparative Binding Analysis of Dipeptidyl Peptidase IV (DPP-4) with Antidiabetic Drugs - An Ab Initio Fragment Molecular Orbital Study.
Topics: Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hydrophobic and Hydrophilic Interactions; Hypoglycemic Agents; Linagliptin; Molecular Docking Simulation; Piperidines; Pyrazoles; Sitagliptin Phosphate; Thiazolidines; Uracil | 2016 |
Evaluation of drug efficacy of DPP-4 inhibitors based on theoretical analysis with pharmacokinetics and pharmacodynamics.
Topics: Adamantane; Algorithms; Area Under Curve; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Piperidines; Pyrrolidines; Treatment Outcome; Uracil; Vildagliptin | 2017 |
Analytical Stability-Indicating Methods for Alogliptin in Tablets by LC-CAD and LC-UV.
Topics: Benzoic Acid; Chromatography, Liquid; Drug Stability; Excipients; Limit of Detection; Mannitol; Piperidines; Tablets; Uracil | 2017 |
Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis.
Topics: Actins; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Blood Urea Nitrogen; Calcium-Binding Proteins; Creatinine; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Fibrosis; Kidney; Macrophages; Male; Mice; Mice, Inbred C57BL; Piperidines; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Renal Insufficiency, Chronic; Transforming Growth Factor beta; Uracil; Ureteral Obstruction | 2017 |
Alogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Alleviates Atrial Remodeling and Improves Mitochondrial Function and Biogenesis in Diabetic Rabbits.
Topics: Animals; Atrial Fibrillation; Atrial Remodeling; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Fibrosis; Heart Atria; Heart Rate; Membrane Potential, Mitochondrial; Mitochondria, Heart; NF-E2-Related Factor 1; Organelle Biogenesis; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Piperidines; Rabbits; Time Factors; Transcription Factor RelA; Transforming Growth Factor beta1; Uracil; Ventricular Function | 2017 |
Comparative study between different simple methods manipulating ratio spectra for the analysis of alogliptin and metformin co-formulated with highly different concentrations.
Topics: Analysis of Variance; Limit of Detection; Linear Models; Metformin; Piperidines; Reproducibility of Results; Spectrophotometry, Ultraviolet; Tablets; Uracil | 2017 |
Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Hospitalization; Humans; Piperidines; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Sitagliptin Phosphate; Uracil | 2017 |
Antidiabetic Drug Alogliptin Protects the Heart Against Ischemia-reperfusion Injury Through GLP-1 Receptor-dependent and Receptor-independent Pathways Involving Nitric Oxide Production in Rabbits.
Topics: Administration, Oral; Animals; Cardiotonic Agents; Glucagon-Like Peptide-1 Receptor; Heart; Hypoglycemic Agents; Male; Myocardial Reperfusion Injury; Nitric Oxide; Piperidines; Rabbits; Signal Transduction; Uracil | 2017 |
Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors.
Topics: Adamantane; Aged; Aged, 80 and over; Autoantibodies; Autoantigens; Collagen Type XVII; Dipeptidyl-Peptidase IV Inhibitors; Epitopes; Female; Humans; Immunoglobulin A; Immunoglobulin E; Immunoglobulin G; Linagliptin; Male; Membrane Glycoproteins; Middle Aged; Nitriles; Non-Fibrillar Collagens; Pemphigoid, Bullous; Piperidines; Pyrrolidines; Sitagliptin Phosphate; Uracil; Vildagliptin | 2018 |
Zinc/alogliptin combination attenuates testicular toxicity induced by doxorubicin in rats: Role of oxidative stress, apoptosis and TGF-β1/NF-κB signaling.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Doxorubicin; Drug Therapy, Combination; Male; NF-kappa B; Oxidative Stress; Piperidines; Random Allocation; Rats; Rats, Wistar; Signal Transduction; Testis; Transforming Growth Factor beta1; Uracil; Zinc | 2018 |
Pharmacokinetics and brain uptake study of novel AMPA receptor antagonist perampanel in SD rats using a validated UHPLC-QTOF-MS method.
Topics: Acetonitriles; Administration, Oral; Animals; Anticonvulsants; Biological Availability; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Male; Nitriles; Piperidines; Pyridones; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Reference Standards; Reproducibility of Results; Tandem Mass Spectrometry; Uracil | 2018 |
Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.
Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Monitoring; Exenatide; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Ligands; Liraglutide; Models, Molecular; Molecular Targeted Therapy; Nitriles; Peptides; Piperidines; Pyrrolidines; Reproducibility of Results; Sitagliptin Phosphate; Uracil; Venoms; Vildagliptin | 2018 |
Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis.
Topics: Animals; Dose-Response Relationship, Drug; Drug Combinations; Hypoglycemic Agents; Liver; Liver Cirrhosis; Mice; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Pioglitazone; Piperidines; Thiazolidinediones; Treatment Outcome; Uracil | 2018 |
Comparative study between UHPLC-UV and UPLC-MS/MS methods for determination of alogliptin and metformin in their pharmaceutical combination.
Topics: Chromatography, High Pressure Liquid; Drug Combinations; Hypoglycemic Agents; Metformin; Piperidines; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tablets; Tandem Mass Spectrometry; Uracil | 2017 |
A guide for using experimental design in chromatographic method development: applied to the analysis of selected anti-diabetic pharmaceutical combinations.
Topics: Chromatography, High Pressure Liquid; Dosage Forms; Drug Combinations; Equipment Design; Hypoglycemic Agents; Metformin; Pioglitazone; Piperidines; Reference Standards; Reproducibility of Results; Solutions; Tablets; Thiazolidinediones; Uracil | 2016 |
Alogliptin alleviates hepatic steatosis in a mouse model of nonalcoholic fatty liver disease by promoting CPT1a expression via Thr172 phosphorylation of AMPKα in the liver.
Topics: AMP-Activated Protein Kinases; Animals; Carnitine O-Palmitoyltransferase; Disease Models, Animal; Gene Expression Regulation, Enzymologic; Male; Mice; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Phosphorylation; Piperidines; Uracil | 2018 |
Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
Topics: Adamantane; Administration, Oral; Adverse Drug Reaction Reporting Systems; Aged; Bayes Theorem; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Humans; Linagliptin; Male; Middle Aged; Piperidines; Practice Guidelines as Topic; Sitagliptin Phosphate; United States; United States Food and Drug Administration; Uracil | 2018 |
A high-performance liquid chromatography-tandem mass spectrometry method for simultaneous determination of imigliptin, its five metabolites and alogliptin in human plasma and urine and its application to a multiple-dose pharmacokinetic study.
Topics: Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Imidazoles; Limit of Detection; Linear Models; Piperidines; Pyridines; Reproducibility of Results; Tandem Mass Spectrometry; Uracil | 2018 |
Smart spectrophotometric methods based on normalized spectra for simultaneous determination of alogliptin and metformin in their combined tablets.
Topics: Drug Combinations; Limit of Detection; Linear Models; Metformin; Piperidines; Reproducibility of Results; Spectrophotometry; Tablets; Uracil | 2018 |
Pd/PTABS: An Efficient Water-Soluble Catalytic System for the Amination of 6-Chloropurine Ribonucleoside and Synthesis of Alogliptin.
Topics: Amination; Catalysis; Hypoglycemic Agents; Magnetic Resonance Spectroscopy; Palladium; Piperidines; Solubility; Uracil; Water | 2018 |
Different daily glycemic profiles after switching from once-daily alogliptin plus twice-daily metformin to their once-daily fixed-dose combination in Japanese type 2 diabetic patients.
Topics: Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Patient Satisfaction; Piperidines; Prospective Studies; Treatment Outcome; Uracil | 2019 |
Alogliptin abates memory injuries of hepatic encephalopathy induced by acute paracetamol intoxication via switching-off autophagy-related apoptosis.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents; Apoptosis; Autophagy; Behavior, Animal; Biomarkers; Chemical and Drug Induced Liver Injury; Dipeptidyl-Peptidase IV Inhibitors; Hepatic Encephalopathy; Hydroxyethylrutoside; Male; Maze Learning; Memory; Memory Disorders; Piperidines; Rats; Rats, Wistar; Uracil | 2018 |
The neurovascular protective effect of alogliptin in murine MCAO model and brain endothelial cells.
Topics: Animals; Brain; Brain Ischemia; Cells, Cultured; Endothelial Cells; Humans; Infarction, Middle Cerebral Artery; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Occludin; Piperidines; Stroke; Uracil; Zonula Occludens-1 Protein | 2019 |
Alogliptin improves endothelial function by promoting autophagy in perivascular adipose tissue of obese mice through a GLP-1-dependent mechanism.
Topics: Adipokines; Adipose Tissue; Animals; Aorta, Thoracic; Autophagy; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Endothelium, Vascular; Glucagon-Like Peptide 1; Male; Mice, Inbred C57BL; Nitric Oxide; Nitric Oxide Synthase Type III; Obesity; Paracrine Communication; Piperidines; Proto-Oncogene Proteins c-akt; Signal Transduction; Uracil; Vasodilation | 2019 |
Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Diastole; Dipeptidyl-Peptidase IV Inhibitors; Fibrosis; Hypertrophy, Left Ventricular; Membrane Potential, Mitochondrial; Mitochondria, Heart; Nuclear Respiratory Factor 1; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Piperidines; Rabbits; Reactive Oxygen Species; Signal Transduction; Stroke Volume; Transcription Factors; Uracil; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Pressure; Ventricular Remodeling | 2018 |
Alogliptin improves survival and health of mice on a high-fat diet.
Topics: Animals; Autophagy; Diet, High-Fat; Disease Models, Animal; Health; Liver; Longevity; Male; Mice; Mice, Inbred C57BL; Mitochondria, Liver; Piperidines; Survival Rate; Uracil | 2019 |
Protective effects of alogliptin against TNF-α-induced degradation of extracellular matrix in human chondrocytes.
Topics: Aggrecans; Cells, Cultured; Chondrocytes; Collagen Type II; Dipeptidyl-Peptidase IV Inhibitors; DNA-Binding Proteins; Extracellular Matrix; Humans; Metalloproteases; Piperidines; Protective Agents; Tumor Necrosis Factor-alpha; Uracil | 2019 |
Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell.
Topics: Animals; Cell Line; Dipeptidyl-Peptidase IV Inhibitors; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Piperidines; Transforming Growth Factor beta; Uracil | 2019 |
Design and Discovery of Novel 1,3,5-Triazines as Dipeptidyl Peptidase-4 Inhibitor against Diabetes.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Design; Drug Discovery; Glucose Tolerance Test; Hypoglycemic Agents; Inhibitory Concentration 50; Male; Mice; Mice, Inbred ICR; Piperidines; Rats; Rats, Wistar; Triazines; Uracil | 2019 |
Alogliptin-induced bullous pemphigoid associated with HLA-DQB1*03:01: a case report.
Topics: Aged; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Female; HLA-DQ beta-Chains; Humans; Pemphigoid, Bullous; Piperidines; Uracil | 2019 |
Effects of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin on Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus.
Topics: Aged; Arterial Pressure; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypertension; Male; Middle Aged; Piperidines; Prospective Studies; Time Factors; Treatment Outcome; Uracil; Vascular Stiffness | 2019 |
Determination of pioglitazone, its metabolite and alogliptin in human plasma by a novel LC-MS/MS method; application to a pharmacokinetic study.
Topics: Chromatography, Liquid; Humans; Linear Models; Pioglitazone; Piperidines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Uracil | 2019 |
Novel spectrofluorimetric quantification of alogliptin benzoate in biofluids exploiting its interaction with 4-chloro-7-nitrobenzofurazan.
Topics: 4-Chloro-7-nitrobenzofurazan; Animals; Benzoates; Fluorescent Dyes; Humans; Male; Molecular Structure; Piperidines; Quantum Theory; Rats; Rats, Wistar; Spectrometry, Fluorescence; Uracil | 2020 |
Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan.
Topics: Adamantane; Adult; Age Factors; Aged; Case-Control Studies; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Incidence; Linagliptin; Male; Middle Aged; Pemphigoid, Bullous; Piperidines; Risk Factors; Sitagliptin Phosphate; Taiwan; Uracil; Vildagliptin; Young Adult | 2020 |
Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Cholesterol; Creatinine; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Linagliptin; Lipid Metabolism; Lipoproteins, HDL; Male; Middle Aged; Piperidines; Pyrazoles; Sitagliptin Phosphate; Thiazolidines; Triglycerides; Uracil; Vildagliptin | 2020 |
Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro.
Topics: Allografts; Animals; Antineoplastic Agents; Axons; Cell Differentiation; Cell Line, Tumor; Cisplatin; Colonic Neoplasms; Dose-Response Relationship, Drug; HCT116 Cells; Humans; Hyperalgesia; Male; Mice; Mice, Inbred BALB C; Neurites; Neuroprotective Agents; Oxaliplatin; PC12 Cells; Peripheral Nervous System Diseases; Piperidines; Rats; Rats, Sprague-Dawley; Sciatic Nerve; Tumor Burden; Uracil | 2020 |
Spectrofluorometric determination of alogliptin an antidiabetic drug in pure and tablet form using fluorescamine, a fluorogenic agent: application to content uniformity test.
Topics: Fluorescamine; Humans; Hypoglycemic Agents; Piperidines; Spectrometry, Fluorescence; Tablets; Uracil | 2020 |
Alogliptin-induced bullous pemphigoid.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Pemphigoid, Bullous; Piperidines; Uracil | 2020 |
Alogliptin reversed hippocampal insulin resistance in an amyloid-beta fibrils induced animal model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Hippocampus; Insulin Resistance; Male; Maze Learning; Peptide Fragments; Piperidines; Random Allocation; Rats; Rats, Wistar; Uracil | 2020 |
Alogliptin attenuates cyclophosphamide-induced nephrotoxicity: a novel therapeutic approach through modulating MAP3K/JNK/SMAD3 signaling cascade.
Topics: Animals; Cyclophosphamide; Inflammation; Male; Oxidative Stress; Piperidines; Rats; Rats, Wistar; Signal Transduction; Uracil | 2022 |
Glucagon-like peptide 1 treatment reverses vascular remodelling by downregulating matrix metalloproteinase 1 expression through inhibition of the ERK1/2/NF-κB signalling pathway.
Topics: Animals; Blood Pressure; Cells, Cultured; Dipeptidyl-Peptidase IV Inhibitors; Down-Regulation; Gene Expression Regulation, Enzymologic; Glucagon-Like Peptide 1; Hypertension; Liraglutide; Male; MAP Kinase Signaling System; Matrix Metalloproteinase 1; Myocytes, Smooth Muscle; NF-kappa B; Piperidines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Uracil; Vascular Remodeling | 2020 |
Unveiling the interaction mechanism of alogliptin benzoate with human serum albumin: Insights from spectroscopy, microcalorimetry, and molecular docking and molecular dynamics analyses.
Topics: Benzoates; Binding Sites; Calorimetry; Circular Dichroism; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Piperidines; Protein Binding; Serum Albumin, Human; Spectrometry, Fluorescence; Thermodynamics; Uracil | 2021 |
Alogliptin Attenuates Lipopolysaccharide-Induced Neuroinflammation in Mice Through Modulation of TLR4/MYD88/NF-κB and miRNA-155/SOCS-1 Signaling Pathways.
Topics: Animals; Behavior, Animal; Cognitive Dysfunction; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Lipopolysaccharides; Male; Mice; MicroRNAs; Myeloid Differentiation Factor 88; Neuroinflammatory Diseases; Neuroprotective Agents; NF-kappaB-Inducing Kinase; Piperidines; Protein Serine-Threonine Kinases; Signal Transduction; Suppressor of Cytokine Signaling 1 Protein; Toll-Like Receptor 4; Uracil | 2021 |
Different chromatographic methods for determination of alogliptin benzoate, metformin hydrochloride, and metformin impurity in bulk and pharmaceutical dosage form.
Topics: Benzoates; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Drug Compounding; Drug Contamination; Metformin; Piperidines; Uracil | 2021 |
Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease.
Topics: Adamantane; Antiviral Agents; Coronavirus 3C Proteases; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Repositioning; Enzyme Assays; Heterocyclic Compounds; Linagliptin; Piperidines; SARS-CoV-2; Sitagliptin Phosphate; Uracil | 2021 |
[Specific features of the use of alogliptin in various groups of patients with type 2 diabetes mellitus: additional results of the ENTIRE study].
Topics: Diabetes Mellitus, Type 2; Humans; Piperidines; Prospective Studies; Uracil | 2020 |
Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry).
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Japan; Piperidines; Prospective Studies; Registries; Uracil | 2021 |
Attenuation of diethyl nitrosamine-induced hepatocellular carcinoma by taxifolin and/or alogliptin: The interplay between toll-like receptor 4, transforming growth factor beta-1, and apoptosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinoma, Hepatocellular; Diethylnitrosamine; Gene Expression Regulation; Hypoglycemic Agents; Liver Neoplasms; Male; Piperidines; Quercetin; Random Allocation; Rats; Rats, Wistar; Toll-Like Receptor 4; Transforming Growth Factor beta1; Uracil | 2021 |
Intestinal Absorption of Alogliptin Is Mediated by a Fruit-Juice-Sensitive Transporter.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Administration, Oral; Animals; Caco-2 Cells; Citrus paradisi; Citrus sinensis; Diabetes Mellitus, Type 2; Food-Drug Interactions; Fruit and Vegetable Juices; Half-Life; HEK293 Cells; Humans; Intestinal Absorption; Male; Malus; Organic Anion Transporters; Piperidines; Rats; Terfenadine; Uracil | 2021 |
Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways.
Topics: Adenylate Kinase; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Blood Pressure; Cardiomegaly; Cardiotonic Agents; Cell Line; Disease Models, Animal; Glucagon-Like Peptide 1; Hypertension; Liraglutide; Male; Morpholines; Myocytes, Cardiac; Piperidines; Rats; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases; Triazines; Uracil | 2021 |
Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China.
Topics: Adamantane; China; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; Drug Therapy, Combination; Humans; Linagliptin; Metformin; Middle Aged; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Uracil; Vildagliptin | 2021 |
Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial.
Topics: Acute Coronary Syndrome; Aged; Body Mass Index; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Incidence; Male; Middle Aged; Piperidines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Uracil; Weight Gain; Weight Loss | 2021 |
An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2022 |
Novel mechanistic insights towards the repositioning of alogliptin in Parkinson's disease.
Topics: Animals; Dimethyl Sulfoxide; Dipeptidyl-Peptidase IV Inhibitors; Drug Repositioning; Glucagon-Like Peptide 1; Male; Parkinsonian Disorders; Piperidines; Rats; Rats, Wistar; Uracil | 2021 |
HPLC-MS Analysis of Four Potential Genotoxic Impurities in Alogliptin Pharmaceutical Materials.
Topics: Chromatography, High Pressure Liquid; DNA Damage; Piperidines; Reproducibility of Results; Tablets; Tandem Mass Spectrometry; Uracil | 2022 |
Hantzsch condensation reaction as a spectrofluorometric method for determination of alogliptin, an antidiabetic drug, in pure form, tablet form, and human and rat plasma.
Topics: Animals; Humans; Hypoglycemic Agents; Piperidines; Rats; Spectrometry, Fluorescence; Tablets; Uracil | 2022 |
Protective effect of alogliptin against cyclophosphamide-induced lung toxicity in rats: Impact on PI3K/Akt/FoxO1 pathway and downstream inflammatory cascades.
Topics: Animals; Antioxidants; Cyclophosphamide; Fibrosis; Lung; Nerve Tissue Proteins; Oxidative Stress; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Uracil | 2022 |
Investigation of the effect of Acai berry on the pharmacokinetics of Atorvastatin, Alogliptin and Empagliflozin: a herb-drug interaction study.
Topics: Animals; Atorvastatin; Benzhydryl Compounds; Euterpe; Glucosides; Herb-Drug Interactions; Piperidines; Rats; Rats, Sprague-Dawley; Uracil | 2022 |
Formulation and Optimization of Alogliptin-Loaded Polymeric Nanoparticles: In Vitro to In Vivo Assessment.
Topics: Drug Carriers; Nanoparticles; Particle Size; Piperidines; Polymers; Uracil | 2022 |